Quantcast

Latest photodynamic therapy Stories

a561f3c429b38d70e80b61fd3540fa0d1
2009-11-18 14:21:20

In an advance with overtones of Star Trek phasers and other sci-fi ray guns, scientists in Canada are reporting development of an internal on-off "switch" that paralyzes animals when exposed to a beam of ultraviolet light. The animals stay paralyzed even when the light is turned off. When exposed to ordinary light, the animals become unparalyzed and wake up. Their study appears in the Journal of the American Chemical Society (JACS). It reports the first demonstration of such a light-activated...

2009-11-10 05:30:00

WILMINGTON, Mass., Nov. 10 /PRNewswire/ -- The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer. This pilot study, which will also appear in the print version of the December issue of...

2009-11-06 14:26:00

WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curhan Ford Investor Summit 2009 on Tuesday, November 10, 2009 at 10:00 a.m. ET at...

2009-10-28 05:30:00

WILMINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units. "The achievement of this milestone signifies that dermatologists in the U.S. and...

2009-10-19 05:30:00

RECEIVES EXCLUSIVE U.S. RIGHTS AND WILL RECEIVE A ROYALTY ON SALES OUTSIDE THE U.S. VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has restructured its agreement with Novartis Pharma AG ("Novartis") to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive U.S. rights to the Visudyne(R) patents to sell and market Visudyne in the U.S. Visudyne, a...

2009-10-14 05:00:00

ST. LOUIS and COLUMBUS, Ohio, Oct. 14 /PRNewswire/ -- The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) has entered into a contract with Global Vision Technologies (GVT) to create and deliver a new, web-based Photo Dynamic Therapy patient registry solution -- ClinicalPURSUIT -- to help streamline the data collection and outcomes analysis process. Photodynamic therapy (PDT) is a treatment...

2009-10-05 06:10:00

A combination of medications and a particular light therapy is effective at treating certain types of head and neck cancers in subtropical climates. In a paper presented at the 2009 American Academy of Otolaryngology "“ Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO in San Diego, researchers from the University of Miami presented findings from a study on dysplasia and carcinomas of the head and neck. It analyzed the effect of photodynamic therapy (PDT), a...

2009-10-04 11:30:00

PHOENIX, Oct. 4 /PRNewswire/ -- The appearance of facial acne scars showed greater improvement with a combination treatment of photodynamic therapy (PDT) and percutaneous collagen induction (PCI or medical needling) with the ENVIRON® Surgical Roll-CIT(TM) compared to PDT alone. The results of the pilot split-face comparison were presented by Hilton Kaplan, MD PhD, Medical Advisor for ENVIRON® distributor DermoGenesis, at the 2009 Joint Annual...

2009-08-11 05:30:00

WILMINGTON, Mass., Aug. 11 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.((R)) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan((R)) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the second quarter ended June 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090810/DC59366LOGO) Financial highlights for the second quarter and first...

2009-06-16 11:31:36

Chemists at the University of California, Santa Cruz, have developed novel compounds that show promise for photodynamic cancer therapy, which uses light-activated drugs to kill tumor cells.The new compounds, called dye-sensitized ruthenium nitrosyls, are absorbed by cancer cells and respond to specific wavelengths of light by releasing nitric oxide, which triggers cell death."For cancer treatment, you want localized delivery of a very high concentration of nitric oxide. We've designed these...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related